Statements (31)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:clinical_trial |
NC T02022260
NC T02022273 NC T02022287 NC T02022294 NC T02022300 |
| gptkbp:contraindication |
severe hepatic impairment
|
| gptkbp:dosage_form |
gptkb:tablet
|
| gptkbp:effective_date |
2014-12-31
|
| gptkbp:form |
extended-release tablet
|
| gptkbp:has_ability |
1 mg
0.5 mg 8 mg 2 mg 16 mg 4 mg 0.125 mg 0.25 mg |
| https://www.w3.org/2000/01/rdf-schema#label |
Orenitram
|
| gptkbp:ingredients |
treprostinil
|
| gptkbp:is_used_for |
pulmonary arterial hypertension
|
| gptkbp:manager |
oral
|
| gptkbp:manufacturer |
gptkb:United_Therapeutics_Corporation
|
| gptkbp:side_effect |
headache
nausea diarrhea jaw pain flushing |
| gptkbp:bfsParent |
gptkb:Treprostinil
gptkb:United_Therapeutics_Corporation |
| gptkbp:bfsLayer |
6
|